





Towards a Metabolomics Platform for Cardiovascular Disease

Robert E. Gerszten, MD


**Cardiology Division and
Center for Immunology & Inflammatory Diseases
Massachusetts General Hospital
&
Broad Institute of Harvard and MIT**

Inflammation & Wound Healing in Cardiovascular Disease






Unanticipated Role of “Intracellular” Metabolites



GPR 99 highly expressed in the renal cortex
Postulated to play a role in BP control
Ligand unknown

Metabolomics Platform




Organic acids, amino acids, nucleotides, carbohydrates, lipids




- Q1 selects and passes only precursor of interest
- Q2 selected precursor is fragmented
- Q3: monitor specific fragment ions

- Sensitivity
- Specificity
- Throughput
- Small sample volumes
- Absolute Quantitation
- Flexibility/Multiplexing
- Utility across species

Mass spec optimization: Tuning




Specificity of the Mass Spectrometer




Reverse phase

Parent Daughter


Choline: 104 ----->60.1




GABA: 104 ----->69.0




Aminoisobutyric acid : 104 ----->57.2




Sensitivity: Limit of Detection and Linear Range



Metabolomics Platform



● Platform Coverage



KEGG database of all known metabolic pathways

Progress in Platform Development

- Sensitivity
 - ng/ml range
- Reproducibility
 - CV <20%
- Comprehensive coverage
 - Approaching 500 metabolites

Challenges in Applying Metabolomics to Human Disease

- **Inherent unpredictability of the onset of pathological states**
- **Inter-individual variability**


“Planned” Myocardial Injury



Current Blood Biomarkers



- None suitable for myocardial *ischemia*

- Existing biomarkers of myocardial *necrosis* (e.g., troponin) are not elevated until many hours after myocardial injury




- Search for new biomarkers has been limited to proteins and constrained by a candidate marker approach

Blood Sampling during “Planned MI”





Exercise Stress Testing Protocol



*Each patient his or her own control
Critical advantage in data analysis*

Predictive Ability of Metabolite Score



Studies of Extreme Exercise: Boston Marathon




Blood Draws



Maximum Exercise Testing in Normal Individuals

| | ETT Cohort (N=26) | CPET Cohort (N=13) |
|-----------------------------|----------------------|-----------------------|
| Age, years | 51 ± 11 | 52 ± 12 |
| Male sex, (%) | 62 | 60 |
| Weight, (lb) | 189 ± 40 | 184 ± 48 |
| Body Mass Index | 29 ± 5 | 27 ± 5 |
| Exercise Duration (min) | 12 ± 2.7 | 8 ± 0.8 |
| Peak VO ₂ (METs) | 12 ± 4 | 9 ± 2 |



Baird
Radionuclidi
de Camera

Arterial Line

Upright Bicycle
Ergometry
-continuous ramp
protocol
-work increased at
12.5 Watts/min

**A cautionary
tale....**

Rapid and noninvasive diagnosis of the presence and severity of coronary heart disease using ^1H -NMR-based metabonomics

Joanne T. Brindle¹, Henrik Antti¹, Elaine Holmes¹, George Tranter¹,
Jeremy K. Nicholson¹, Hugh W.L. Bethell², Sarah Clarke², Peter M. Schofield²,
Elaine McKilligin³, David E. Mosedale⁴ & David J. Grainger⁴

Published online: 25 November 2002; doi:10.1038/nm1202-802

**nature
medicine**

TECHNICAL REPORTS

Proton NMR analysis of plasma is a weak predictor
of coronary artery disease

Heide L Kirschenlohr¹, Julian L Griffin¹, Sarah C Clarke², Ranyl Rhydwen², Andrew A Grace^{1,2},
Peter M Schofield², Kevin M Brindle¹ & James C Metcalfe¹

Metabolomics Platform

Metabolism of Complex Carbohydrates

Biodegradation of Xenobiotics

Metabolism of Complex Lipids

Peptide Metabolism



Ru

Greg

Arvind

Oded

Carbohydrate Metabolism

Metabolism of Other Amino Acids



Vamsi

Amino Acid Metabolism



Steve Carr



Rob

Energy Metabolism

Met Cofactor

is of tablets